Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Class Action Lawsuit Details - The lawsuit is titled Shouse v. Tempus AI, Inc., and it allows purchasers of Tempus AI common stock between August 6, 2024, and May 27, 2025, to seek appointment as lead plaintiff by August 12, 2025 [1]. - The lawsuit claims that Tempus AI inflated the value of contract agreements, had questionable joint ventures, and engaged in potentially unethical billing practices [3]. - On May 28, 2025, a research report from Spruce Point Capital Management raised concerns about Tempus AI's management and operations, resulting in a stock price drop of over 19% [4]. Group 2: Allegations Against Tempus AI - Allegations include that Tempus AI's joint venture with SoftBank appeared to involve "round-tripping" capital, and that AstraZeneca reduced its financial commitments through a questionable payment structure [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is under scrutiny for aggressive billing practices that could threaten its sustainability [3]. - The issues raised in the lawsuit indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM